kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - inne środki przeciwnowotworowe - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
lenalidomide sandoz 2,5 mg kapsułki twarde
sandoz gmbh - lenalidomidum - kapsułki twarde - 2,5 mg
lenalidomide sandoz 5 mg kapsułki twarde
sandoz gmbh - lenalidomidum - kapsułki twarde - 5 mg
lenalidomide sandoz 7,5 mg kapsułki twarde
sandoz gmbh - lenalidomidum - kapsułki twarde - 7,5 mg
lenalidomide sandoz 10 mg kapsułki twarde
sandoz gmbh - lenalidomidum - kapsułki twarde - 10 mg
lenalidomide sandoz 15 mg kapsułki twarde
sandoz gmbh - lenalidomidum - kapsułki twarde - 15 mg
lenalidomide sandoz 20 mg kapsułki twarde
sandoz gmbh - lenalidomidum - kapsułki twarde - 20 mg
lenalidomide sandoz 25 mg kapsułki twarde
sandoz gmbh - lenalidomidum - kapsułki twarde - 25 mg
lenalidomide zentiva 2,5 mg kapsułki twarde
zentiva, k.s. - lenalidomidum - kapsułki twarde - 2,5 mg
lenalidomide zentiva 5 mg kapsułki twarde
zentiva, k.s. - lenalidomidum - kapsułki twarde - 5 mg